Results 11 to 20 of about 421,641 (311)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

Neurology and Therapy, 2020
Introduction Compared with the non-Hispanic/non-Latino population, Hispanic/Latino patients with multiple sclerosis (MS) are reported to exhibit greater disease severity.
Angel Chinea, Lilyana Amezcua, Wendy Vargas, Annette Okai, Mitzi J. Williams, Ray Su, Becky Parks, Jason P. Mendoza, James B. Lewin, Cynthia C. Jones   +9 more
doaj   +1 more source

Personalised profiling to identify clinically relevant changes in tremor due to multiple sclerosis

BMC Medical Informatics and Decision Making, 2019
Background There is growing interest in sensor-based assessment of upper limb tremor in multiple sclerosis and other movement disorders. However, previously such assessments have not been found to offer any improvement over conventional clinical ...
David G. Western, Simon A. Neild, Rosemary Jones, Angela Davies-Smith   +3 more
doaj   +1 more source

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

Neurology and Therapy, 2019
Introduction Multiple sclerosis (MS) patients of African descent have increased risk for disease progression and may be less responsive to disease-modifying therapy.
Annette F. Okai, Lilyana Amezcua, Regina R. Berkovich, Angel R. Chinea, Keith R. Edwards, Brian Steingo, Aljoeson Walker, Alan K. Jacobs, Nadia Daizadeh, Mitzi J. Williams, the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators   +10 more
doaj   +1 more source

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

Neurology and Therapy, 2020
Introduction Black or African American (black/AA) patients with multiple sclerosis (MS) are reported to exhibit greater disease severity compared with non-black or non-AA patients.
Mitzi J. Williams, Lilyana Amezcua, Annette Okai, Darin T. Okuda, Stanley Cohan, Ray Su, Becky Parks, Jason P. Mendoza, James B. Lewin, Cynthia C. Jones   +9 more
doaj   +1 more source

Development and evaluation of a website with patients experiences of multiple sclerosis: a mixed methods study

BMC Neurology, 2022
Background A variety of management options (e.g., disease-modifying therapy, lifestyle interventions, rehabilitation) are available for persons with relapsing-remitting multiple sclerosis (MS).
Anna Sippel, Jutta Scheiderbauer, Désirée Eklund, Sigrid Arnade, Stephan Schmidt, Ingo Kleiter, Rebecca Morrison, Christopher Kofahl, Christoph Heesen   +8 more
doaj   +1 more source

A Case of Neuromyelitis Optica: Puerto Rican Woman with an Increased Time Lag to Diagnosis and a High Response to Eculizumab Therapy

Case Reports in Neurological Medicine, 2022
A link between intractable hiccups, as the initial symptom, and a possible neuromyelitis optica spectrum disorder (NMOSD) diagnosis is confusing but vital and may not be made by health care providers (HCPs) if they are not aware of the 2015 NMOSD ...
Ramón Vega, Benjamín González, Kiara Ortiz, Viviana Martínez, David Carmona, Ivonne Vicente, Javier Chapa, Ángel Chinea   +7 more
doaj   +1 more source

Is There a Need to Differentiate Atypical Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorders (NMOSD)? The Pros and Cons: A Systematic Review (PP-21) [PDF]

Neurology Letters, 2023
Introduction: Most atypical inflammatory demyelinating diseases (IDD) exhibit pathological characteristics comparable to multiple sclerosis (MS). We conducted this systematic review to investigate the atypical cases that appear to be intermediate between
Sepideh Paybast, Fatemeh Baghalha, Ali Emami, Abdorreza Naser Moghadasi   +3 more
doaj  

Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials

Trials, 2022
Background Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the optimisation of recruitment strategies.
Thomas Williams, Sarah Alexander, James Blackstone, Floriana De Angelis, Nevin John, Anisha Doshi, Judy Beveridge, Marie Braisher, Emma Gray, Jeremy Chataway, on behalf of the MS-SMART and MS-STAT2 Investigators   +10 more
doaj   +1 more source

Comparison of Neurite Orientation Dispersion and Density Imaging and Two-Compartment Spherical Mean Technique Parameter Maps in Multiple Sclerosis

Frontiers in Neurology, 2021
Background: Neurite orientation dispersion and density imaging (NODDI) and the spherical mean technique (SMT) are diffusion MRI methods providing metrics with sensitivity to similar characteristics of white matter microstructure.
Daniel Johnson, Daniel Johnson, Antonio Ricciardi, Antonio Ricciardi, Wallace Brownlee, Baris Kanber, Baris Kanber, Ferran Prados, Ferran Prados, Ferran Prados, Sara Collorone, Enrico Kaden, Enrico Kaden, Ahmed Toosy, Ahmed Toosy, Daniel C. Alexander, Claudia A. M. Gandini Wheeler-Kingshott, Claudia A. M. Gandini Wheeler-Kingshott, Claudia A. M. Gandini Wheeler-Kingshott, Olga Ciccarelli, Olga Ciccarelli, Francesco Grussu, Francesco Grussu   +22 more
doaj   +1 more source

Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)—study protocol for a randomised controlled trial

Trials, 2021
Introduction Multiple sclerosis is a chronic inflammatory, degenerative disease of the central nervous system manifesting at first with relapses in about 85% of cases.
Anne Christin Rahn, Lisa Wenzel, Andrea Icks, Alexander Stahmann, Jutta Scheiderbauer, Kristina Grentzenberg, Markus Vomhof, Joseph Montalbo, Tim Friede, Christoph Heesen, Sascha Köpke   +10 more
doaj   +1 more source